Assessment of biotechnology drugs: what are the issues?

[1]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Somerfield,et al.  Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A J Moskowitz,et al.  Capturing the unexpected benefits of medical research. , 1998, The New England journal of medicine.

[4]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[5]  A. Detsky,et al.  Measuring health outcomes--putting gains into perspective. , 1998, The New England journal of medicine.

[6]  A. Adgey,et al.  An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. , 1998, European heart journal.

[7]  Daan J.A. Crommelin,et al.  Pharmaceutical Biotechnology: An Introduction for Pharmacists and Pharmaceutical Scientists , 1997 .

[8]  R. Milne,et al.  Rationing of growth hormone: who reviews the experts? , 1997, The Lancet.

[9]  R. Lea,et al.  Rationing of growth hormone: who reviews the experts? , 1997, The Lancet.

[10]  S. Nussey.  Rationing of growth hormone: who reviews the experts? , 1997, The Lancet.

[11]  R. Deber,et al.  Regulating biotechnology: a rational-political model of policy development. , 1997, Health policy.

[12]  D. Blaise,et al.  Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.

[13]  J. DiMasi,et al.  Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 , 1996, Clinical pharmacology and therapeutics.

[14]  S. Shalet,et al.  Growth hormone deficiency and replacement in adults , 1996, BMJ.

[15]  van der Veen Ea,et al.  Growth hormone deficiency and substitution in adults , 1996 .

[16]  M. Donaldson.  Jury still out on growth hormone for normal short stature and Turner's syndrome , 1996, The Lancet.

[17]  F. Rutten,et al.  Economic evaluation and health care decision-making. , 1996, Health policy.

[18]  V Torri,et al.  Beware of Surrogate Outcome Measures , 1996, International Journal of Technology Assessment in Health Care.

[19]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[20]  D. Huhn,et al.  Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Platt,et al.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? , 1995, The New England journal of medicine.

[22]  E. Wagner,et al.  Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. , 1995, Journal of clinical epidemiology.

[23]  D. Blaise,et al.  Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. , 1994, Bone Marrow Transplantation.

[24]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[25]  J. Urquhart,et al.  Variability in patterns of drug usage. , 1994, The Journal of pharmacy and pharmacology.

[26]  J. Avorn,et al.  Evaluating drugs after their approval for clinical use. , 1993, The New England journal of medicine.

[27]  J. Luce.  Introduction of new technology into critical care practice: A history of HA‐1A human monoclonal antibody against endotoxin , 1993, Critical care medicine.

[28]  S. Lehrman.  Challenge to growth hormone trial , 1993, Nature.

[29]  G. Lyman,et al.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. , 1993, Journal of the National Cancer Institute.

[30]  T. Denton,et al.  Alternative Perspectives on the Biased Foundations of Medical Technology Assessment , 1993, Annals of Internal Medicine.

[31]  P. Speelman,et al.  [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients]. , 1993, Nederlands tijdschrift voor geneeskunde.

[32]  J. Schellekens,et al.  [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis]. , 1993, Nederlands tijdschrift voor geneeskunde.

[33]  T. Jw,et al.  [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo]. , 1993 .

[34]  van Hout Ba,et al.  [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]. , 1993, Nederlands tijdschrift voor geneeskunde.

[35]  G. Carlon,et al.  Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. , 1993, JAMA.

[36]  R. Bone,et al.  Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome) , 1992, JAMA.

[37]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[38]  M. Trněný,et al.  [Hematopoietic growth factors. Biology and clinical applications]. , 1992, Casopis lekaru ceskych.

[39]  R. Danner,et al.  Anti-endotoxin monoclonal antibodies. , 1992, The New England journal of medicine.

[40]  Ziegler Ej,et al.  Anti-endotoxin monoclonal antibodies. , 1992, The New England journal of medicine.

[41]  H. Glick,et al.  Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. , 1991, JAMA.

[42]  C. Sprung,et al.  The HA-1A monoclonal antibody for gram-negative sepsis. , 1991, The New England journal of medicine.

[43]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[44]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[45]  Rein Vos,et al.  Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists , 1990 .

[46]  J. Wennberg,et al.  Outcomes research, cost containment, and the fear of health care rationing. , 1990, The New England journal of medicine.

[47]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[48]  Robert L. Stamper,et al.  Haste Makes Waste , 1985 .

[49]  M. Adams,et al.  Human Growth Hormone , 1972, Journal of the Royal College of Physicians of London.

[50]  E. Vellenga,et al.  An economic model to assess the savings from a clinical application of haematopoietic growth factors. , 1996, European journal of cancer.

[51]  H. Buurma,et al.  TECHNOLOGY ASSESSMENT STAAT WEER OP DE AGENDA , 1994 .

[52]  D. Richel,et al.  Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. , 1994, European journal of cancer.

[53]  J. von Pawel,et al.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.

[54]  D. P. Allersma.  CENTOXIN : HOE NU VERDER ? , 1992 .

[55]  D. Andrulis,et al.  Assessing medical technologies. , 1978, Bulletin of the New York Academy of Medicine.

[56]  Germaine Greer,et al.  van Deventer H , 1968 .